Osteopontin: A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses

Satoshi Konno, Nobuyuki Hizawa, Masaharu Nishimura, Shau Ku Huang

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

Original languageEnglish
Pages (from-to)355-359
Number of pages5
JournalAllergology International
Volume55
Issue number4
DOIs
Publication statusPublished - Jan 1 2006
Externally publishedYes

Fingerprint

Bee Venoms
Osteopontin
Venoms
Immunotherapy
Immunoglobulin E
Biomarkers
Hypersensitivity
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Cluster Analysis
Insects
Therapeutics
Serum

Keywords

  • Biomarker
  • Clustering
  • Mechanism
  • Microarray
  • Osteopontin (OPN)
  • Venom immunotherapy (VIT)

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Osteopontin : A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses. / Konno, Satoshi; Hizawa, Nobuyuki; Nishimura, Masaharu; Huang, Shau Ku.

In: Allergology International, Vol. 55, No. 4, 01.01.2006, p. 355-359.

Research output: Contribution to journalReview article

@article{f9946f2a36594868ba0fd489f6a66d49,
title = "Osteopontin: A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses",
abstract = "Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.",
keywords = "Biomarker, Clustering, Mechanism, Microarray, Osteopontin (OPN), Venom immunotherapy (VIT)",
author = "Satoshi Konno and Nobuyuki Hizawa and Masaharu Nishimura and Huang, {Shau Ku}",
year = "2006",
month = "1",
day = "1",
doi = "10.2332/allergolint.55.355",
language = "English",
volume = "55",
pages = "355--359",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "4",

}

TY - JOUR

T1 - Osteopontin

T2 - A potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses

AU - Konno, Satoshi

AU - Hizawa, Nobuyuki

AU - Nishimura, Masaharu

AU - Huang, Shau Ku

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

AB - Venom immunotherapy (VIT) is proven to be curative for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. We report herein the discovery of a leading candidate biomarker, osteopontin (OPN), for VIT. From cDNA microarray and clustering analyses, an increased expression of OPN was found in patients who completed 5-6 years of VIT and discontinued therapy for 3-6 years as compared with the untreated group. A significantly higher level of serum OPN was found in the completed treatment group as compared with the untreated group. Following VIT, kinetically increased levels of OPN associated with reduced venom specific IgE levels were noted in subjects with large local allergic reactions to venom. These findings together with the fact that OPN is involved in Th1-associated immune response strongly suggest a role of OPN as a functional biomarker for VIT.

KW - Biomarker

KW - Clustering

KW - Mechanism

KW - Microarray

KW - Osteopontin (OPN)

KW - Venom immunotherapy (VIT)

UR - http://www.scopus.com/inward/record.url?scp=33846041789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846041789&partnerID=8YFLogxK

U2 - 10.2332/allergolint.55.355

DO - 10.2332/allergolint.55.355

M3 - Review article

C2 - 17130676

AN - SCOPUS:33846041789

VL - 55

SP - 355

EP - 359

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 4

ER -